|
Quotes & Info
|
| HSP > SEC Filings for HSP > Form 8-K on 19-Aug-2009 | All Recent SEC Filings |
19-Aug-2009
Other Events
In a form 8-K filed on August 14, 2009, Hospira, Inc. ("Company") reported that, pursuant to legal proceedings not related to the safety of our product, the FDA suspended the ANDA approval for our oxaliplatin products. On August 18, 2009, the court order initiating the ANDA suspension was dissolved. On August 19, 2009, the Company received notice that the previously suspended ANDA has been reinstated by the FDA. The Company has resumed shipments of the product. Legal proceedings related to this product are ongoing.
|
|